Eraxis (anidulafungin) / RaQualia - LARVOL DELTA

Factors Associated with Candidemia After Living Donor Liver Transplantation: A Case-Control Study. (PubMed, J Clin Med) - " Univariate analysis revealed significant associations with prolonged intubation (p < 0.001), bile leaks (p < 0.001), relaparotomy (p < 0.001), chronic renal disease (p = 0.011), hepatocellular carcinoma (p = 0.011), and the use of antimicrobials including meropenem (p = 0.048), linezolid (p = 0.005), tigecycline (p = 0.045), third-generation cephalosporins (p = 0.003), anidulafungin (p < 0.001), fluconazole (p = 0.006), mycophenolate (p = 0.011), and total parenteral nutrition (TPN) (p = 0.049). Prolonged intubation, bile leaks, antifungal exposure, and lack of CMV prophylaxis are independently associated with higher odds of candidemia after LDLT. Targeted prophylaxis, prudent antimicrobial stewardship, and timely biliary intervention may reduce fungal morbidity and mortality in post-transplant patients."

Journal • Chronic Kidney Disease • Hepatocellular Cancer • Infectious Disease • Nephrology • Oncology • Renal Disease • Solid Tumor • Transplantation

Phylogenomic diversity of clinical Saccharomyces cerevisiae and the prevalence of probiotic-derived isolates in a tertiary care center in Hungary. (PubMed, Microbiol Spectr) - "Caspofungin and anidulafungin retained consistent in vitro activity, whereas amphotericin B and micafungin exhibited broader MIC distributions. By integrating genome sequencing, antifungal susceptibility testing, and patient data, we demonstrate that yeasts considered safe in food and probiotic products may nevertheless cause infections in vulnerable individuals. These findings highlight the need for clade-level molecular genetic typing of Saccharomyces samples, cautious probiotic administration, and sustained clinical vigilance."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pediatrics

Community-Onset Fungemias: Epidemiology and Genomic Characterization at a Tertiary-Care Hospital in Barcelona, Spain. (PubMed, J Fungi (Basel)) - "No isolate was resistant to anidulafungin, micafungin, or amphotericin B; one N. glabratus showed reduced susceptibility to caspofungin. Echinocandin resistance was not observed; azole resistance was uncommon. WGS provided precise speciation and actionable insight into resistance mechanisms, including a putatively novel PDR1 G857V in N. glabratus."

Journal • Cardiovascular • Infectious Disease

Fatal Complications in Candida parapsilosis Endocarditis-A Case Report. (PubMed, J Fungi (Basel)) - "The patient died despite efficient antifungal therapy, initially with Anidulafungin in monotherapy and later in combination with Fluconazole. The reported case emphasizes the importance of managing fungal endocarditis, the need for urgent diagnostic attention and multidisciplinary team approach by infectious diseases specialist, cardiologist, neurologist and heart surgeon."

Journal • Cardiovascular • Diabetes • Hematological Disorders • Hematological Malignancies • Infectious Disease • Metabolic Disorders • Myelodysplastic Syndrome • Myocardial Infarction • Oncology • Thrombosis

Association between genomic single nucleotide polymorphisms and susceptibility of Talaromyces marneffei. (PubMed, Fungal Genet Biol) - "To reveal the association between genomic single nucleotide polymorphisms (SNPs) and susceptibility to T. marneffei, we sequenced the genomes of 15 clinical isolates of T. marneffei and analyzed the association between their SNPs and susceptibilities to 5-fluorouracil, anidulafungin, posaconazole, voriconazole, fluconazole, caspofungin, amphotericin B, micafungin, and itraconazole. Nine, one, one, and 14 SNP loci were potentially correlated with fluconazole, micafungin, posaconazole, and caspofungin susceptibilities, respectively. These results provide valuable genomic data for further analysis of drug resistance mechanisms and treatment strategies."

Journal • Infectious Disease

Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights. (PubMed, J Antimicrob Chemother) - "This multicentre study demonstrates the emergence of fluconazole-NWT W. anomalus in Indian hospitals, predominantly affecting neonates, with a high mortality. Resistance was associated with ERG11 mutations, efflux pump overexpression and biofilm formation. These findings highlight that the drug-resistant W. anomalus fungemia is an emerging concern."

Journal • Acute Respiratory Distress Syndrome • Respiratory Diseases • ABCB1

Pulmonary Aspergilloma in Immunocompromised Patients: Expanding Treatment Horizons with Voriconazole and Anidulafungin (APSR 2025) - "Traditional treatment includes intravenous Amphotericin B and oral Itraconazole. It presents a viable, less invasive alternative to surgery, especially in high-risk individuals. The regression of the fungus ball supports the growing role of modern antifungal combinations in managing complex pulmonary fungal infections."

Clinical • Asthma • Cardiovascular • Diabetes • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Respiratory Diseases • Tuberculosis

Epidemiology and Clinical Outcomes of Hematologic Patients with Proven and Probable Invasive Fungal Infections: A Latin American Tertiary Care Centre Experience (ASH 2023) - "4%) patients were receiving antifungal prophylaxis (fluconazole n = 24, itraconazole n = 13, posaconazole n = 3, voriconazole n = 3, anidulafungin n = 2). Mortality rates were higher, possibly explained by the exclusion of possible IFI cases, higher proportion of active primary disease, and limited antifungal prophylaxis. Better survival among patients with aspergillosis, suggest that current diagnostic tests lead to earlier diagnosis and treatment with an impact on patients' prognosis."

Clinical • Clinical data • Bone Marrow Transplantation • Candidiasis • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Respiratory Diseases • Transplantation

Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia (ASH 2024) - "When examining which AFP was at steady-state at IFI diagnosis the plurality of pts were on voriconazole (n=28) with n=20 on no AFP, n=12 on isavuconazole, and n=10 on anidulafungin. Adverse ELN 2022 risk and rrAML were highly predictive of mortality after IFI diagnosis. These results support that AFP effectively prevents IFI amongst patients with deep, protracted neutropenia."

Biomarker • Clinical • Acute Myelogenous Leukemia • Candidiasis • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Respiratory Diseases • PHF6

Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis. (PubMed, BMC Microbiol) - "In vitro susceptibility against nine antifungals (amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, 5-flucytosine) was determined using Sensititre YeastOne YO10 panels. In addition, most of the strains demonstrated biofilm formation ability, with evident genus-level heterogeneity. These findings emphasize the imperative of species-level identification and consideration of genus-specific traits to guide effective management of this life-threatening infection."

Journal • Infectious Disease

Echinococcal Cyst of the Liver Primarily Infected with Candida glabrata. (PubMed, Surg Infect (Larchmt)) - "Anidulafungin was initiated with a loading dose of 200 mg, followed by a daily dose of 100 mg... Fungal infections should be considered in patients with an infected echinococcal cyst of the liver. Understanding of the etiology and epidemiology, along with early and rapid detection of C. glabrata, is necessary for prompt treatment."

Journal • Infectious Disease • Oncology • Pain • Pancreatic Cancer • CRP

Rapid detection of anidulafungin and fluconazole susceptibility profiles of clinical Candida strains by MALDI-TOF MS. (PubMed, Acta Microbiol Immunol Hung) - "The reproducibility of the MS-AFST assay ranged from 45% to 75%, highest for C. parapsilosis and fluconazole. The study suggests that the MALDI-TOF MS method for assessing antifungal susceptibility in Candida strains is promising but requires further improvements for enhancing the accuracy and reproducibility."

Journal • Infectious Disease

CANDIDA GLABRATA PNEUMONIA IN AN IMMUNOCOMPROMISED PATIENT UNDERGOING CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA: A CASE REPORT AND LITERATURE REVIEW (CHEST 2025) - "CASE PRESENTATION: A 67-year-old female with AML on chemotherapy with Azacitidine, Venetoclax and Gilteritinib presented with shortness of breath and a cough producing purulent sputum...Despite being initially treated with piperacillin-tazobactam, patient remained febrile...Guidelines favor echinocandins(Anidulafungin 200mg once, then 100mg daily for >14 days after first negative blood culture[4]) over amphotericin B for efficacy and safety...Stable patients with negative blood cultures may transition to oral fluconazole (800mg daily) voriconazole (200–300mg twice daily)[6].Similar reports show that immunosuppressive therapy, such as imatinib for CML, can predispose patients to Candida glabrata pneumonia, emphasizing the need for careful monitoring[7]... While C. glabrata pneumonia is rare among AML patients, this case aligns with existing literature emphasizing the vulnerability of immunocompromised individuals to invasive fungal infections. It underscores the need..."

Case report • Clinical • Review • Acute Myelogenous Leukemia • Candidiasis • Cough • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

IMPACT OF ANTIFUNGAL PROPHYLAXIS ON TRANSPLANT-RELATED MORTALITY IN MISMATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A PROSPECTIVE EXPERIENCE FROM A SINGLE TRANSPLANT PROGRAM (SIE 2025) - "As GVHD prophylaxis, all received CSA, MMF, and PT-Cy 50 mg/kg for 2 days and 94.5% (n=34, CMV+) received letermovir,as CMV prophylaxis...Anidulafungin-related toxicity was observed in 36.1% (n=13) of patients, exclusively as liver WHO grading <2 and resolved within 3 days of stopping the drug...1 year NRM Months Cumulative Risk Figure 1. 100 days and 1 year NRM."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

First Report of Candida auris Candidemia in Portugal: Genomic Characterisation and Antifungal Resistance-Associated Genes Analysis. (PubMed, J Fungi (Basel)) - "All isolates exhibited resistance to fluconazole and amphotericin B according to the recently established EUCAST epidemiological cut-offs (ECOFFs). Most of the isolates showed a resistant phenotype to anidulafungin and micafungin...Identifying known and novel mutations highlights the evolution of antifungal resistance mechanisms in C. auris. These findings underscore the need for further research to understand C. auris resistance pathways and to guide effective clinical management strategies."

Journal

Emergence of multidrug-resistant Candidozyma auris in southern China: a multicenter study on genetic diversity and antifungal resistance. (PubMed, Front Microbiol) - "The resistance rates to caspofungin, micafungin, and anidulafungin were 7.4, 7.4, and 3.7%, respectively. Genetic clade I and clade III C. auris strains are prevalent in southern China and present high levels of resistance to fluconazole. Controlling the spread of C. auris in this region presents significant challenges for public health management."

Clinical • Journal

MARIO: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (clinicaltrials.gov) - P3 | N=68 | Active, not recruiting | Sponsor: Scynexis, Inc. | Recruiting ➔ Active, not recruiting | N=220 ➔ 68

Enrollment change • Enrollment closed • Candidiasis

WHEN INFECTION MASKS MALIGNANCY: ESOPHAGEAL MEDIASTINAL FISTULA AND LUNG ABSCESS AS INITIAL PRESENTATION OF SQUAMOUS CELL CARCINOMA (CHEST 2025) - "She was treated with Zosyn and anidulafungin, followed by Augmentin and fluconazole for a total of 6 weeks. The complex presentation in this case underscores the challenge of distinguishing infectious processes from malignancies, and the need for close follow-up and repeated evaluations in such cases."

Addiction (Opioid and Alcohol) • Cough • Diabetes • Esophageal Cancer • Gastrointestinal Disorder • Infectious Disease • Metabolic Disorders • Oncology • Respiratory Diseases • Squamous Cell Carcinoma • Thoracic Cancer • Type 2 Diabetes Mellitus • CRP

A FATAL CASE OF SERRATIA MARCESCENS CAVITARY PNEUMONIA IN AN HIV PATIENT: A GRAVE COMPLICATION (CHEST 2025) - "Broad-spectrum antibiotics (vancomycin, meropenem, anidulafungin) and tobramycin were initiated, and cultures from the endotracheal aspirate and urine confirmed the same organism. Although bronchopneumonia is an usual manifestation of Serratia marcescens, cavitary pneumonia can occur. Despite timely recognition and adequate treatment, Serratia marcescens cavitary penumonia can be multidrug resistant and prove fatal in patients of HIV with low CD4 counts as ours."

Clinical • Acute Kidney Injury • Cardiovascular • Cough • Hematological Disorders • Human Immunodeficiency Virus • Hypotension • Infectious Disease • Metabolic Disorders • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • Tuberculosis • Urology • CD4

THE FUNGI ISN'T SO FUN ANYMORE (CHEST 2025) - "Blood cultures confirmed fungemia from Candida auris that was sensitive to Amphotericin B and Anidulafungin which the patient was initiated on. This case highlights an emerging alternative for treating Candida Auris fungemia that is resistant to conventional antifungals. Fosmanogepix is available for compassionate use as part of a clinical trial and should be considered for relevant patient population."

Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Pituitary Gland Carcinoma • Renal Disease • Septic Shock • Type 2 Diabetes Mellitus

Minimum Inhibitory Concentrations of Anidulafungin as a Potential Predictor of Biocide Susceptibility of Clade 1 Candidozyma (Candida) auris Isolates. (PubMed, Microbiologyopen) - "Anidulafungin MIC was the strongest predictor of biocide sensitivity, followed by amphotericin B, flucytosine, and isavuconazole, while other virulence factors showed little or no value. This proof-of-concept study demonstrates, for the first time, that a decision tree model trained on antifungal MIC profiles can predict the susceptibility of C. auris strains to triclosan, chlorine, and chlorhexidine. Although biocide susceptibility testing was performed to establish reference thresholds, the final predictive framework relied solely on anidulafungin MIC values, suggesting that such models may reduce the need for routine biocide testing in future surveillance studies."

Journal • Infectious Disease

A Rare Case of Necrotizing Soft Tissue Infection in the Labium Resulting From Candida glabrata. (PubMed, Cureus) - "Thus, the patient's antibiotic treatment was escalated, and antifungal treatment was initiated with anidulafungin. The patient was discharged on the 32nd postoperative day. Delay in diagnosis and initiation of surgical treatment for NSTIs is the most significant factor affecting morbidity, which ranges between 20% and 40%. Despite the nonspecific signs and symptoms that often lead to misdiagnosis, timely recognition and intervention are crucial and can lead to a favorable outcome, as in this case."

Journal • Dermatology • Infectious Disease • Pain

In Vitro Induction of Resistance to Fluconazole and Caspofungin in Candida parapsilosis Complex Species: Implications for Virulence and Cross-Resistance to Other Antifungals. (PubMed, Microb Pathog) - "Notably, induced resistance to one antifungal agent influenced susceptibility to other antifungals, with an inverse relationship between the MICs of azoles (FLC, itraconazole, and voriconazole) and echinocandins (CSF, anidulafungin, and micafungin). Our findings highlight the adaptability of C. parapsilosis complex species to antifungal pressure, underscoring the need for continuous surveillance and the development of novel therapeutic strategies to manage infections caused by these pathogens. The increase in biofilm formation following antifungal exposure presents additional challenges for infection management."

Journal • Preclinical • Infectious Disease

Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates. (PubMed, Sci Rep) - "We applied this method in a comprehensive screen of 92 clinical C. albicans isolates for three antifungals-amphotericin B, fluconazole, and anidulafungin-yielding assessments of a total of 276 distinct combinations of antifungals and isolates. These findings underscore the need for isolate-specific testing in clinical settings. This proposed assay aims to present a solution to that as a scalable high throughput approach to this clinical problem."

Journal • Infectious Disease

Character Virulence Association Factors and Gene Mutation Mediating Multidrug Resistance Phenotypes in Candidozyma duobushaemulonii. (PubMed, Mycopathologia) - "MDR in the cd1 strain extended to 5-fluorocytosine (5-FC) and anidulafungin (ANI), whereas the cd3 strain showed intermediate posaconazole (PSZ) resistance distinct to the cd2 strain. Gene expression analysis recorded various regulatory situations among strains. These analyses provide a complete resistance-virulence matrix for C. duobushaemulonii, establishing baseline characteristics for epidemiological surveillance and a reference framework for future comparative studies."

Journal • Candidiasis • Infectious Disease • CD2